Literature DB >> 15061760

CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells.

John D Hayball1, Bruce W S Robinson, Richard A Lake.   

Abstract

CD4(+) T cells are activated upon recognition of peptide antigen in the context of MHC class II molecules, expressed by specialized APC. In this study, we show that CD4(+) T cells cross-compete for antigenic complexes on the surface of APC, inhibiting activation of other potentially reactive T cells of the same and differing specificities. T cells with either a higher affinity receptor for antigen or which have undergone prior activation compete more efficiently than low affinity or resting T cells. This implies that T-cell avidity for the APC is primarily responsible for the competitive advantage. We also provide evidence that the mechanism for competition is steric hindrance of the surface of the APC, rather than T-cell-mediated sequestration or internalization of antigenic complexes. This is because removal of competing T cells restores the antigenic potential of the APC, and APC fixation does not abrogate competition. Demonstration that competition for access to APC can also occur in vivo suggests that this process may represent a physiologically important mechanism for influencing the quality and quantity of CD4(+) T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15061760     DOI: 10.1046/j.0818-9641.2004.01233.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  8 in total

1.  Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.

Authors:  Dipak S Pisal; Matthew P Kosloski; C Russell Middaugh; Richard B Bankert; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2012-03-02       Impact factor: 3.534

2.  Antigenic competition in CD4+ T cell responses in a randomized, multicenter, double-blind clinical HIV vaccine trial.

Authors:  Esper G Kallas; Nicole A Grunenberg; Chenchen Yu; Bryce Manso; Giuseppe Pantaleo; Martin Casapia; Lindsey R Baden; Javier Valencia; Magdalena Sobieszczyk; Hong Van Tieu; Mary Allen; John Hural; Barney S Graham; James Kublin; Peter B Gilbert; Lawrence Corey; Paul A Goepfert; M Juliana McElrath; R Paul Johnson; Yunda Huang; Nicole Frahm
Journal:  Sci Transl Med       Date:  2019-11-20       Impact factor: 17.956

3.  Immunogenicity and protective efficacy of tuberculosis DNA vaccines combining mycolyl-transferase Ag85A and phosphate transport receptor PstS-3.

Authors:  Marta Romano; Virginie Roupie; Xiao M Wang; Olivier Denis; Fabienne Jurion; Pierre-Yves Adnet; Rachid Laali; Kris Huygen
Journal:  Immunology       Date:  2006-07       Impact factor: 7.397

4.  Antigen-experienced T cells limit the priming of naive T cells during infection with Leishmania major.

Authors:  Peter M Gray; Steven L Reiner; Deborah F Smith; Paul M Kaye; Phillip Scott
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

5.  High epitope expression levels increase competition between T cells.

Authors:  Almut Scherer; Marcel Salathé; Sebastian Bonhoeffer
Journal:  PLoS Comput Biol       Date:  2006-07-12       Impact factor: 4.475

6.  Cross-priming induces immunodomination in the presence of viral MHC class I inhibition.

Authors:  Elvin J Lauron; Liping Yang; Jabari I Elliott; Maria D Gainey; Daved H Fremont; Wayne M Yokoyama
Journal:  PLoS Pathog       Date:  2018-02-14       Impact factor: 6.823

7.  CD4+ Recent Thymic Emigrants Are Recruited into Granulomas during Leishmania donovani Infection but Have Limited Capacity for Cytokine Production.

Authors:  John W J Moore; Lynette Beattie; Mohamed Osman; Benjamin M J Owens; Najmeeyah Brown; Jane E Dalton; Asher Maroof; Paul M Kaye
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

8.  Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Authors:  Laetitia Sordé; Sebastian Spindeldreher; Ed Palmer; Anette Karle
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.